Advertisement
INCY vs RPRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and RPRX is a Hold.
INCY in +4.28% Uptrend, rising for three consecutive days on October 15, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INCY advanced for three days, in 210 of 328 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Indicator exited the oversold zone, 19 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 56%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 60 cases where INCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 55%.
INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INCY as a result. In 55 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
INCY moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INCY crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for INCY entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.987) is normal, around the industry mean (26.782). P/E Ratio (15.901) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (437.542).
RPRX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RPRX turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 32 of 52 cases over the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RPRX's RSI Oscillator exited the oversold zone, 14 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 54%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 50 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 176 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for RPRX crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
RPRX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RPRX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.804) is normal, around the industry mean (26.782). P/E Ratio (31.382) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). RPRX's Dividend Yield (0.016) is considerably higher than the industry average of (0.000). P/S Ratio (12.870) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
INCY | RPRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 44 | 27 | |
SMR RATING 1..100 | 33 | 97 | |
PRICE GROWTH RATING 1..100 | 47 | 40 | |
P/E GROWTH RATING 1..100 | 65 | 6 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RPRX's Valuation (1) in the Pharmaceuticals Major industry is significantly better than the same rating for INCY (88) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than INCY’s over the last 12 months.
RPRX's Profit vs Risk Rating (27) in the Pharmaceuticals Major industry is in the same range as INCY (44) in the Biotechnology industry. This means that RPRX’s stock grew similarly to INCY’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is somewhat better than the same rating for RPRX (97) in the Pharmaceuticals Major industry. This means that INCY’s stock grew somewhat faster than RPRX’s over the last 12 months.
RPRX's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as INCY (47) in the Biotechnology industry. This means that RPRX’s stock grew similarly to INCY’s over the last 12 months.
RPRX's P/E Growth Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (65) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than INCY’s over the last 12 months.
| INCY | RPRX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 56% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 55% | 1 day ago 53% |
| Momentum ODDS (%) | 1 day ago 57% | 1 day ago 57% |
| MACD ODDS (%) | N/A | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 59% |
| Advances ODDS (%) | 2 days ago 64% | 1 day ago 56% |
| Declines ODDS (%) | 4 days ago 55% | 11 days ago 49% |
| BollingerBands ODDS (%) | 1 day ago 60% | 1 day ago 61% |
| Aroon ODDS (%) | 1 day ago 57% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green while RPRX’s FA Score has 3 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- RPRX’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 4 TA indicator(s) are bullish while RPRX’s TA Score has 5 bullish TA indicator(s).
- INCY’s TA Score: 4 bullish, 5 bearish.
- RPRX’s TA Score: 5 bullish, 5 bearish.
Price Growth
INCY (@Biotechnology) experienced а +0.25% price change this week, while RPRX (@Biotechnology) price change was +7.08% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
INCY is expected to report earnings on Oct 29, 2026.
RPRX is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement